These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
721 related articles for article (PubMed ID: 30228778)
41. Tackling Resistance to Cancer Immunotherapy: What Do We Know? Gondhowiardjo SA; Handoko ; Jayalie VF; Apriantoni R; Barata AR; Senoaji F; Utami IJW; Maubere F; Nuryadi E; Giselvania A Molecules; 2020 Sep; 25(18):. PubMed ID: 32911646 [TBL] [Abstract][Full Text] [Related]
42. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer. Marginean EC; Melosky B Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224 [TBL] [Abstract][Full Text] [Related]
43. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937 [TBL] [Abstract][Full Text] [Related]
44. Bispecific antibody based therapeutics: Strengths and challenges. Thakur A; Huang M; Lum LG Blood Rev; 2018 Jul; 32(4):339-347. PubMed ID: 29482895 [TBL] [Abstract][Full Text] [Related]
45. Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity. Janji B; Berchem G; Chouaib S Front Immunol; 2018; 9():887. PubMed ID: 29922284 [TBL] [Abstract][Full Text] [Related]
47. First person: Antoni Ribas, MD, PhD: The physician-scientist from the University of California at Los Angeles researches how new therapies for patients with advanced malignant melanoma can help to overcome resistance to treatment. Printz C Cancer; 2018 Mar; 124(6):1097-1098. PubMed ID: 29509327 [No Abstract] [Full Text] [Related]
48. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. Sweis RF; Galsky MD Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246 [TBL] [Abstract][Full Text] [Related]
49. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277 [TBL] [Abstract][Full Text] [Related]
50. The emerging role of immune checkpoint based approaches in AML and MDS. Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300 [TBL] [Abstract][Full Text] [Related]
51. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. Wang K; Baldwin GS; Nikfarjam M; He H World J Gastroenterol; 2018 Sep; 24(33):3709-3723. PubMed ID: 30197477 [TBL] [Abstract][Full Text] [Related]
52. Tumor-Secreted Extracellular Vesicles Regulate T-Cell Costimulation and Can Be Manipulated To Induce Tumor-Specific T-Cell Responses. Zhao X; Yuan C; Wangmo D; Subramanian S Gastroenterology; 2021 Aug; 161(2):560-574.e11. PubMed ID: 33895168 [TBL] [Abstract][Full Text] [Related]
54. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Picard E; Verschoor CP; Ma GW; Pawelec G Front Immunol; 2020; 11():369. PubMed ID: 32210966 [TBL] [Abstract][Full Text] [Related]
55. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer. Thomas J; Leal A; Overman MJ Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280 [TBL] [Abstract][Full Text] [Related]
56. [Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden]. Cohen R; Heran M; Pudlarz T; Hilmi M; Tournigand C; André T; Rousseau B Bull Cancer; 2019 Feb; 106(2):151-161. PubMed ID: 30638897 [TBL] [Abstract][Full Text] [Related]
57. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494 [TBL] [Abstract][Full Text] [Related]
58. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H Front Immunol; 2018; 9():1878. PubMed ID: 30158932 [TBL] [Abstract][Full Text] [Related]
59. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer. Chen Y; Zheng X; Wu C Front Immunol; 2021; 12():792691. PubMed ID: 34925375 [TBL] [Abstract][Full Text] [Related]
60. Nutraceuticals in colorectal cancer: A mechanistic approach. Rossi M; Mirbagheri SEYEDS; Keshavarzian A; Bishehsari F Eur J Pharmacol; 2018 Aug; 833():396-402. PubMed ID: 29935172 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]